Nutritional Intervention in Chronic Fatigue Syndrome and Fibromyalgia (CFS/FMS) A Unique Porcine Serum Polypeptide Nutritional Supplement
Jacob Teitelbaum1, *, Gaetano Morello1, Sarah Goudie1
Article Information
Identifiers and Pagination:
Year: 2020Volume: 13
First Page: 52
Last Page: 58
Publisher ID: TOPAINJ-13-52
DOI: 10.2174/1876386302013010052
Article History:
Received Date: 29/06/2020Revision Received Date: 12/10/2020
Acceptance Date: 16/10/2020
Electronic publication date: 31/12/2020
Collection year: 2020
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Background:
Clinical experience suggested that a unique porcine serum polypeptide extract, used in hospitals for people with severe malnutrition, serendipitously resulted in a dramatic improvement in many fibromyalgia cases.
Aims:
The study aims to determine the effectiveness of a unique polypeptide serum extract in improving the symptoms of CFS and fibromyalgia (CFS/FMS).
Methods:
An open-label prospective study of 43 people with CFS or Fibromyalgia recruited worldwide.
Interventions:
Four 500 mg tablets twice daily for five weeks.
Outcome Measures:
Assessed baseline at five weeks of treatment using a VAS(1-10 points) rating energy, sleep, cognitive function, pain, overall well-being, anxiety, and digestive health, as well as the FIQR. The primary outcome measure was the pre- and post-treatment VAS composite score for the first five symptoms.
Results:
43 subjects completed the three-week treatment trial. 60.5% of subjects rated themselves as improved, with 18.6% rating themselves as much better.
In the 60.5% of subjects that rated themselves as improved, the significant average improvement was seen in all categories:
1. 69.4% increase in energy(p<.001)
2. 69.2% increase in overall well-being(<.001)
3. 53.8% improvement in sleep(<.001)
4. 60.5% improvement in mental clarity(<.001)
5. 37.9% decrease in pain(<.013)
6. 34.8% decrease in anxiety(<.001)
7. 54.6% improvement in digestive symptoms(<.001)
8. FIQR 59.2 to 39.3(<.001)
In six individuals who also had pre- and post IgG antibody levels, total IgG increased by 13.8% on average, with similar improvements seen in the IgG 1-4 subsets.
Conclusion:
Recovery Factors® resulted in markedly improved energy, sleep, cognition, pain relief, calming, digestion and overall well-being in those with CFS/FMS.
Clinical Trial Registration Number: NCT04381793.
